AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HM Capital","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Onco Immune, Inc. Raises $56 Million Series B Financing for Novel Cancerandd Covid-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$425.0 million","newsHeadline":"Merck to Acquire OncoImmune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune\u2019s SACCOVID\u2122 (CD24Fc) Exhibits Superb Therapeutic Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Discontinues Development of SARS-CoV-2\/COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Discontinue Development of MK-7110 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for MK-7110

    Menu

    MK-7110

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck to Discontinue Development of MK-7110 for COVID-19

              Details:

              Merck reported that, based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: MK-7110

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates

              Details:

              Merck has reported that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: CD24Fc

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for Critical COVID-19

              Details:

              Under the agreement, Merck will receive up to approximately $356 million for manufacturing and supply of approximately 60,000-100,000 doses of MK-7110 to the U.S. Government through June 30, 2021 to meet the government’s Operation Warp Speed goals.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: MK-7110

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: U.S. Government

              Deal Size: $356.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement December 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck to Acquire OncoImmune

              Details:

              Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19. Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: CD24Fc

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: $425.0 million Upfront Cash: $425.0 million

              Deal Type: Acquisition November 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy

              Details:

              Data from 203 participants show that severe or critical COVID-19 patients treated with SACCOVID exhibited significantly faster recovery and significantly reduced disease progression to death or respiratory failure than those receiving placebo.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: Saccovid

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Onco Immune, Inc. Raises $56 Million Series B Financing for Novel Cancerandd Covid-19 Therapeutics

              Details:

              Oncoimmune will use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline. OncoImmune currently has two Phase III clinical programs to evaluate its lead product CD24Fc.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: CD24Fc

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: HM Capital

              Deal Size: $56.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing September 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19

              Details:

              The first 70 patients have been randomized and received either CD24Fc or placebo as the treatment for severe COVID-19.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in COVID-19 Patients

              Details:

              The new trial will test the impact of OncoImmune’s flagship product, CD24Fc, in dampening inflammation caused by virus-induced cellar injuries, in severe COVID-19 patients.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection

              Details:

              The trial is intended for use in HIV patients who have been receiving the traditional antiretroviral therapies that control, but do not cure, HIV infection.

              Lead Product(s): MK-7110

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

              Details:

              The study, compares safety and efficacy data of CD24Fc when used in combination with standard of care GVHD prophylaxis compared to placebo and historical controls.

              Lead Product(s): MK-7110,Methotrexate,Tacrolimus

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY